B V Batotsyrenov Selected Research

Remaxol

1/2016	[[Features of Pharmacological Correction of Alcoholic Fatty Liver Disease in Patients with Acute Ethanol Intoxication].]
1/2013	[Correction of metabolic disorders during treatment of alcohol-induced liver injuries in patients with acute alcoholic intoxication].
4/2012	[Comparative evaluation of clinical efficacy of drugs remaxol and ademetionine in patients with acute ethanol poisoning complicated by the toxic damage of the liver].
1/2012	[Pharmacological correction of toxic liver damage in patients with heavy forms of acute ethanol intoxication].
1/2012	[Characteristics of the pharmacological treatment of toxic liver damage in patients with an alcohol abused syndrome and an acute severe ethanol poison].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

B V Batotsyrenov Research Topics

Disease

22	Poisoning 01/2020 - 07/2001
8	Hypoxia (Hypoxemia) 01/2018 - 03/2002
8	Disease Progression 01/2018 - 01/2011
7	Coma (Comas) 01/2020 - 03/2002
3	Brain Diseases (Brain Disorder) 01/2013 - 11/2011
3	Delirium 01/2013 - 01/2012
2	Respiratory Insufficiency (Respiratory Failure) 01/2020 - 03/2002
2	Alcohol Withdrawal Delirium (Delirium Tremens) 01/2016 - 01/2012
1	Body Weight (Weight, Body) 01/2020
1	Respiratory Acidosis 01/2020
1	Lactic Acidosis 01/2020
1	Hyperammonemia 01/2020
1	Brain Edema (Cerebral Edema) 01/2020
1	Pneumonia (Pneumonitis) 01/2018
1	Psychotic Disorders (Schizoaffective Disorder) 01/2018
1	Alcoholic Fatty Liver 01/2016
1	Hyperlactatemia 01/2016
1	Alcoholism (Alcohol Abuse) 01/2015
1	Acidosis 01/2013
1	Binge Drinking 04/2012
1	Lead Poisoning (Poisoning, Lead) 03/2012
1	Peritonitis 01/2011
1	Myocardial Infarction 05/2010
1	Heart Failure 05/2010
1	Critical Illness (Critically Ill) 11/2005
1	Wounds and Injuries (Trauma) 03/2002

Drug/Important Bio-Agent (IBA)

9	ReamberinIBA 01/2018 - 01/2010
7	Ethanol (Ethyl Alcohol)IBA 01/2020 - 07/2001
6	cytoflavinIBA 01/2020 - 01/2010
5	RemaxolIBA 01/2016 - 01/2012
5	Free RadicalsIBA 01/2015 - 07/2001
4	Oxygen (Dioxygen)IBA 01/2015 - 03/2002
4	PoisonsIBA 01/2013 - 11/2005
4	Pharmaceutical PreparationsIBA 11/2011 - 07/2001
3	AntioxidantsIBA 01/2016 - 05/2010
2	AcidsIBA 01/2020 - 01/2018
2	Carbon MonoxideIBA 01/2013 - 01/2012
2	S-Adenosylmethionine (Ademetionine)IBA 01/2013 - 04/2012
2	Antidepressive Agents (Antidepressants)IBA 03/2002 - 07/2001
2	Antipsychotic Agents (Antipsychotics)IBA 03/2002 - 07/2001
1	Sevoflurane (Ultane)FDA LinkGeneric 01/2020
1	4- chloro- 3',6'- dimethyl- 2,2'- iminodibenzoate (TO 115)IBA 01/2020
1	Carbon DioxideIBA 01/2020
1	barbituric acid (barbiturate)IBA 01/2018
1	Phenobarbital (Luminal)FDA Link 01/2018
1	Urea (Carbamide)FDA LinkGeneric 01/2016
1	AlbuminsIBA 01/2016
1	Methanol (Carbinol)IBA 01/2013
1	AntidotesIBA 01/2013
1	AlkaliesIBA 01/2013
1	Lipid PeroxidesIBA 03/2012
1	Methadone (Dolophine)FDA LinkGeneric 03/2012
1	Psychotropic Drugs (Psychoactive Drugs)IBA 01/2012
1	Opiate AlkaloidsIBA 11/2011
1	Surface-Active Agents (Surfactants)IBA 03/2002
1	SolutionsIBA 03/2002
1	Narcotics (Narcotic Analgesics)IBA 03/2002
1	Succinic Acid (Succinate)IBA 07/2001

Therapy/Procedure

15	Therapeutics 01/2020 - 07/2001
4	Duration of Therapy 01/2016 - 01/2012
3	Critical Care (Surgical Intensive Care) 01/2016 - 07/2001
2	Resuscitation 04/2012 - 01/2012
1	Intravenous Administration 01/2013
1	Renal Dialysis (Hemodialysis) 01/2013
1	Length of Stay 11/2011